Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD16-positive, CD56-dim natural killer cell, human | 9 studies | 20% ± 4% | |
natural killer cell | 8 studies | 19% ± 4% | |
CD16-negative, CD56-bright natural killer cell, human | 6 studies | 21% ± 4% | |
CD8-positive, alpha-beta T cell | 5 studies | 20% ± 2% | |
T cell | 5 studies | 26% ± 12% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 19% ± 3% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 17% ± 2% | |
lymphocyte | 3 studies | 26% ± 6% |
Insufficient scRNA-seq data for expression of NLRC3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 600.69 | 653 / 653 | 98% | 5.25 | 590 / 605 |
brain | 99% | 338.87 | 2610 / 2642 | 98% | 2.67 | 691 / 705 |
breast | 99% | 265.13 | 453 / 459 | 95% | 3.84 | 1065 / 1118 |
lung | 100% | 874.94 | 578 / 578 | 92% | 3.90 | 1062 / 1155 |
kidney | 100% | 412.30 | 89 / 89 | 91% | 4.28 | 823 / 901 |
prostate | 100% | 418.77 | 244 / 245 | 88% | 2.07 | 443 / 502 |
stomach | 99% | 333.48 | 357 / 359 | 83% | 3.28 | 238 / 286 |
esophagus | 96% | 266.44 | 1390 / 1445 | 86% | 3.09 | 157 / 183 |
uterus | 100% | 327.81 | 170 / 170 | 80% | 2.55 | 369 / 459 |
intestine | 100% | 828.42 | 965 / 966 | 75% | 2.35 | 397 / 527 |
ovary | 99% | 246.72 | 178 / 180 | 71% | 1.59 | 307 / 430 |
adrenal gland | 95% | 210.51 | 245 / 258 | 75% | 1.56 | 172 / 230 |
bladder | 100% | 384.67 | 21 / 21 | 62% | 1.82 | 310 / 504 |
pancreas | 73% | 99.44 | 238 / 328 | 88% | 3.25 | 156 / 178 |
skin | 74% | 127.18 | 1347 / 1809 | 78% | 3.56 | 368 / 472 |
liver | 92% | 190.28 | 209 / 226 | 36% | 0.93 | 146 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 17.51 | 29 / 29 |
spleen | 100% | 3960.88 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1594.82 | 920 / 929 | 0% | 0 | 0 / 0 |
adipose | 99% | 315.52 | 1188 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 96% | 256.64 | 1281 / 1335 | 0% | 0 | 0 / 0 |
heart | 96% | 230.29 | 826 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 5.10 | 40 / 45 |
muscle | 81% | 118.18 | 654 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 0.55 | 20 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0048147 | Biological process | negative regulation of fibroblast proliferation |
GO_0032687 | Biological process | negative regulation of interferon-alpha production |
GO_0032715 | Biological process | negative regulation of interleukin-6 production |
GO_1900226 | Biological process | negative regulation of NLRP3 inflammasome complex assembly |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_1900016 | Biological process | negative regulation of cytokine production involved in inflammatory response |
GO_0050680 | Biological process | negative regulation of epithelial cell proliferation |
GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
GO_0051898 | Biological process | negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_1901223 | Biological process | negative regulation of non-canonical NF-kappaB signal transduction |
GO_0045824 | Biological process | negative regulation of innate immune response |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0032688 | Biological process | negative regulation of interferon-beta production |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0042110 | Biological process | T cell activation |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0034451 | Cellular component | centriolar satellite |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005524 | Molecular function | ATP binding |
GO_0036312 | Molecular function | phosphatidylinositol 3-kinase regulatory subunit binding |
GO_0005515 | Molecular function | protein binding |
GO_0003674 | Molecular function | molecular_function |
Gene name | NLRC3 |
Protein name | NLRC3 (NOD3 protein, isoform CRA_c) NLR family CARD domain containing 3 (NOD3 protein, isoform CRA_d) NLR family CARD domain containing 3 NLR family CARD domain-containing protein 3 (CARD15-like protein) (Caterpiller protein 16.2) (CLR16.2) (NACHT, LRR and CARD domains-containing protein 3) (Nucleotide-binding oligomerization domain protein 3) |
Synonyms | NOD3 hCG_2036791 |
Description | FUNCTION: Negative regulator of the innate immune response . Attenuates signaling pathways activated by Toll-like receptors (TLRs) and the DNA sensor STING/TMEM173 in response to pathogen-associated molecular patterns, such as intracellular poly(dA:dT), but not poly(I:C), or in response to DNA virus infection, including that of Herpes simplex virus 1 (HSV1) (By similarity) . May affect TLR4 signaling by acting at the level of TRAF6 ubiquitination, decreasing the activating 'Lys-63'-linked ubiquitination and leaving unchanged the degradative 'Lys-48'-linked ubiquitination . Inhibits the PI3K-AKT-mTOR pathway possibly by directly interacting with the posphatidylinositol 3-kinase regulatory subunit p85 (PIK3R1/PIK3R2) and disrupting the association between PIK3R1/PIK3R2 and the catalytic subunit p110 (PIK3CA/PIK3CB/PIK3CD) and reducing PIK3R1/PIK3R2 activation. Via its regulation of the PI3K-AKT-mTOR pathway, controls cell proliferation, predominantly in intestinal epithelial cells (By similarity). May also affect NOD1- or NOD2-mediated NF-kappa-B activation . Might also affect the inflammatory response by preventing NLRP3 inflammasome formation, CASP1 cleavage and IL1B maturation . . |
Accessions | ENST00000359128.10 [Q7RTR2-1] Q7RTR2 H3BLT9 ENST00000615877.4 [Q7RTR2-3] ENST00000324659.12 ENST00000618137.1 A0A087WZ24 C3VPR7 |